Arigami Takaaki, Natsugoe Shoji, Uenosono Yoshikazu, Mataki Yuko, Ehi Katsuhiko, Higashi Hiroshi, Arima Hideo, Yanagida Shigehiro, Ishigami Sumiya, Hokita Shuichi, Aikou Takashi
Department of Surgical Oncology and Digestive Surgery, Field of Oncology, Course of Advanced Therapeutics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Ann Surg. 2006 Mar;243(3):341-7. doi: 10.1097/01.sla.0000201453.65534.f1.
To determine the adequacy of sentinel node (SN) concept based on micrometastasis using immunohistochemistry (IHC) and reverse transcription-polymerase chain reaction (RT-PCR) in gastric cancer.
The SN concept has recently been introduced in gastrointestinal tract cancers. The precise detection of lymph node metastasis including micrometastasis is important for SN navigation surgery.
Sixty-one patients with gastric cancer who were preoperatively diagnosed with T1-T2 (cT1-T2) and N0 (cN0) were enrolled. They underwent standard radical gastrectomy with lymph node dissection. One day before surgery, 4 mCi of (99m)Technetium-tin colloid was endoscopically injected into the submucosa around the tumor. During surgery, radioisotope uptake in the lymph node was measured using Navigator GPS. All dissected lymph nodes were examined by RT-PCR in addition to hematoxylin and eosin staining and IHC.
Sentinel nodes were identified in all patients (100%). The incidences of metastasis determined by hematoxylin and eosin and IHC were 8.2% (5 of 61) and 13.1% (8 of 61), respectively. Micrometastases undetectable by IHC were identified in 14 patients (23.0%) by RT-PCR. Only 1 patient had micrometastasis detectable by RT-PCR in lymph nodes other than SN, but this patient had a cT2 tumor. In patients with cT1 and cN0 tumors, the false negative and accuracy rates were 0% and 100%, respectively.
Although the incidence of micrometastasis detected by RT-PCR was quite high, SN navigation identified such metastasis in all patients except one. Thus, the SN concept was applicable to patients with cT1 and cN0 gastric cancer, even when micrometastasis was detectable by RT-PCR.
采用免疫组织化学(IHC)和逆转录聚合酶链反应(RT-PCR)确定基于微转移的前哨淋巴结(SN)概念在胃癌中的适用性。
SN概念最近已被引入胃肠道癌症。精确检测包括微转移在内的淋巴结转移对于SN导航手术很重要。
纳入61例术前诊断为T1-T2(cT1-T2)和N0(cN0)的胃癌患者。他们接受了标准根治性胃切除术及淋巴结清扫术。术前一天,通过内镜将4毫居里的锝-锡胶体注入肿瘤周围黏膜下层。手术期间,使用Navigator GPS测量淋巴结中的放射性同位素摄取。除苏木精-伊红染色和IHC外,对所有切除的淋巴结进行RT-PCR检测。
所有患者(100%)均识别出前哨淋巴结。苏木精-伊红染色和IHC确定的转移发生率分别为8.2%(61例中的5例)和13.1%(61例中的8例)。RT-PCR在14例患者(23.0%)中检测到IHC无法检测到的微转移。仅1例患者在SN以外的淋巴结中有RT-PCR可检测到的微转移,但该患者为cT2肿瘤。在cT1和cN0肿瘤患者中,假阴性率和准确率分别为0%和100%。
尽管RT-PCR检测到的微转移发生率相当高,但SN导航在除1例患者外的所有患者中均识别出了此类转移。因此,SN概念适用于cT1和cN0胃癌患者,即使RT-PCR可检测到微转移。